4,4'-[(苯基甲基)亚氨基]二丁腈 | 78217-67-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4,4'-[(苯基甲基)亚氨基]二丁腈
• 英文名称: N,N-Bis(3-cyanopropyl)-benzylamine
• 英文别名: 1,7-dicyano-N-benzyl-4-azaheptane；N,N-bis(3-cyanopropyl)benzylamine；N-benzyl-5-aza-nonanedinitrile；5-Benzyl-5-azanonanedinitrile；N,N-Bis (3-cyanopropyl) benzylamine；4,4'-[(Phenylmethyl)imino]bisbutanenitrile；4-[benzyl(3-cyanopropyl)amino]butanenitrile
• CAS: 78217-67-1
• 化学式: C₁₅H₁₉N₃
• 分子量: 241.336
• InChiKey: XXDXUMIXKZPAGC-UHFFFAOYSA-N

物化性质

• 溶解度：
  可溶于DCM、乙酸乙酯、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  50.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4,4'-[(苯基甲基)亚氨基]二丁腈 在 palladium dihydroxide 、 镍 sodium hydroxide 、 氢气 作用下， 以 乙醇 为溶剂， 生成 N-(4-氨基丁基)-1,4-丁烷二胺
  参考文献：
  名称：

  Xylylated dimers of putrescine and polyamines: influence of the polyamine backbone on spermidine transport inhibition

  摘要：

  Dimeric norspermidine and spermidine derivatives are strong competitive inhibitors of polyamine transport. A xylyl tether was used for the dimerization of various triamines and spermine via a secondary amino group, and of putrescine via an ether or an amino group. Dimerization of putrescine moieties potentiates their ability to compete against spermidine transport to a much greater extent than for triamine dimers. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00668-1
• 作为产物：
  描述：

  苄胺 生成 4,4'-[(苯基甲基)亚氨基]二丁腈
  参考文献：
  名称：

  BERGERON, R. J. ,, JR.

  摘要：

  DOI：

文献信息

• Cationic amphiphiles containing ester or ether-linked lipophilic groups
  申请人：Genzyme Corporation

  公开号：US05840710A1

  公开（公告）日：1998-11-24

  Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile. Novel and highly effective plasmid constructs are also disclosed, including those that are particularly effective at providing gene therapy for clinical conditions complicated by inflammation. Additionally, targeting of organs for gene therapy by intravenous administration of therapeutic compositions is described.

  提供了一种新型的阳离子两性分子，有助于将生物活性（治疗性）分子输送到细胞内。这些两性分子包含从类固醇、单或双烷胺基或烷基或酰基团衍生的亲脂基团；以及从胺、烷胺或多烷基胺衍生的在生理pH下可质子化的阳离子基团。还提供了通常通过将一个或多个阳离子两性分子的分散液与治疗分子接触而制备的治疗组合物。根据本发明的实践，可以将可输送到细胞内的治疗分子包括DNA、RNA和多肽。本发明的治疗组合物的代表性用途包括提供基因治疗，以及将反义多核苷酸或生物活性多肽输送到细胞中。关于用于基因治疗的治疗组合物，DNA通常以质粒的形式提供，以与阳离子两性分子结合。还公开了新型且高效的质粒构建物，包括那些在为临床炎症并发症复杂的情况下提供基因治疗方面特别有效的构建物。此外，描述了通过静脉给药治疗组合物来定位器官进行基因治疗的方法。
• Cationic amphiphiles containing dialkylamine lipophilic groups for
  申请人：Genzyme Corporation

  公开号：US05719131A1

  公开（公告）日：1998-02-17

  Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile. Novel and highly effective plasmid constructs are also disclosed, including those that are particularly effective at providing gene therapy for clinical conditions complicated by inflammation. Additionally, targeting of organs for gene therapy by intravenous administration of therapeutic compositions is described.

  提供了一种新型的阳离子两性分子，有助于将生物活性（治疗性）分子输送到细胞内。这些两性分子包含从类固醇、单或双烷胺基或烷基或酰基团衍生的亲脂基团；以及从胺、烷胺或多烷胺衍生、在生理pH下可质子化的阳离子基团。还提供了通常通过将一个或多个阳离子两性分子的分散液与治疗分子接触而制备的治疗组合物。根据本发明的实践，可以将可输送到细胞内的治疗分子包括DNA、RNA和多肽。本发明的治疗组合物的代表性用途包括提供基因治疗，以及将反义多核苷酸或生物活性多肽输送到细胞中。关于用于基因治疗的治疗组合物，DNA通常以质粒的形式提供，用于与阳离子两性分子结合。还公开了新型且高效的质粒构建物，包括那些在为临床炎症并发症复杂的情况下提供基因治疗方面特别有效的构建物。此外，还描述了通过静脉给药治疗组合物来定位器官进行基因治疗的方法。
• Cationic amphiphile compositions for intracellular delivery of
  申请人：Genzyme Corporation

  公开号：US05939401A1

  公开（公告）日：1999-08-17

  Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. By this invention, such cationic amphiphile is used in a state in which it is capable of accepting additional protons, i.e., it is not fully protonated. For purposes of this invention, cationic amphiphiles may be considered to encompass four general categories: (A) T-shaped/steroid-based amphiphiles; (B) T-shaped/non steroid-based amphiphiles; (C) non T-shaped/steroid based amphiphiles and (D) non T-shaped/non steroid-based amphiphiles.

  提供了一种新型阳离子两性分子，可促进生物活性（治疗性）分子进入细胞。通过这一发明，这种阳离子两性分子在能够接受额外质子的状态下使用，即未完全质子化。根据本发明的目的，阳离子两性分子可被认为包括四个一般类别：（A）T形/类固醇基两性分子；（B）T形/非类固醇基两性分子；（C）非T形/类固醇基两性分子和（D）非T形/非类固醇基两性分子。
• Cationic amphiphiles containing amino acid or dervatized amino acid
  申请人：Genzyme Corporation

  公开号：US05767099A1

  公开（公告）日：1998-06-16

  Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile. Novel and highly effective plasmid constructs are also disclosed, including those that are particularly effective at providing gene therapy for clinical conditions complicated by inflammation. Additionally, targeting of organs for gene therapy by intravenous administration of therapeutic compositions is described.

  提供了一种新型的阳离子两性分子，有助于将生物活性（治疗性）分子输送到细胞内。这些两性分子包含从类固醇、单或双烷胺基或烷基或酰基团衍生的亲脂基团；以及从胺、烷胺或多烷基胺衍生、在生理pH下可质子化的阳离子基团。还提供了通常通过将一个或多个阳离子两性分子的分散液与治疗分子接触而制备的治疗组合物。根据本发明的实践，可以将DNA、RNA和多肽等治疗分子输送到细胞内。本发明的治疗组合物的代表性用途包括提供基因治疗，以及将反义多核苷酸或生物活性多肽输送到细胞中。关于用于基因治疗的治疗组合物，DNA通常以质粒的形式提供，用于与阳离子两性分子结合。还公开了新型且高效的质粒构建物，包括那些在为临床炎症并发症复杂的情况提供基因治疗方面特别有效的构建物。此外，描述了通过静脉给药治疗组合物来实现基因治疗的器官靶向。
• Cationic amphiphile/DNA complexes
  申请人：Genzyme Corporation

  公开号：US05948767A1

  公开（公告）日：1999-09-07

  Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile. Novel and highly effective plasmid constructs are also disclosed, including those that are particularly effective at providing gene therapy for clinical conditions complicated by inflammation. Additionally, targeting of organs for gene therapy by intravenous administration of therapeutic compositions is described.

  提供了新型阳离子两性分子，可促进生物活性（治疗）分子进入细胞。这些两性分子包含从类固醇、单或二烷基胺或烷基或酰基团派生的亲脂性基团；以及来源于胺、烷基胺或多烷基胺的，在生理pH下可质子化的阳离子基团。还提供了典型的治疗组合物，通常是通过将一个或多个阳离子两性分子的分散液与治疗分子接触而制备的。根据本发明的实践，可以将可用于细胞内传递的治疗分子包括DNA、RNA和多肽。本发明的治疗组合物的代表性用途包括提供基因治疗，以及将反义多核苷酸或生物活性多肽递送到细胞中。对于用于基因治疗的治疗组合物，DNA通常以质粒的形式提供，以与阳离子两性分子形成复合物。还披露了新颖且高效的质粒构建物，包括那些特别有效地为临床情况复杂化的炎症提供基因治疗的构建物。此外，描述了通过静脉给药治疗组合物来定位器官进行基因治疗的方法。